PetMed Express Stock Forecast, Price & News

PetMed Express (NASDAQ:PETS) Frequently Asked Questions

Is PetMed Express a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PetMed Express in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PetMed Express stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PETS, but not buy additional shares or sell existing shares.
View analyst ratings for PetMed Express or view top-rated stocks.

How has PetMed Express' stock price been impacted by COVID-19 (Coronavirus)?

PetMed Express' stock was trading at $25.95 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PETS stock has increased by 4.1% and is now trading at $27.02.
View which stocks have been most impacted by COVID-19.

When is PetMed Express' next earnings date?

PetMed Express is scheduled to release its next quarterly earnings announcement on Tuesday, January 18th 2022.
View our earnings forecast for PetMed Express.

How were PetMed Express' earnings last quarter?

PetMed Express, Inc. (NASDAQ:PETS) announced its quarterly earnings data on Sunday, October, 24th. The company reported $0.31 EPS for the quarter, missing analysts' consensus estimates of $0.34 by $0.03. The business had revenue of $67.39 million for the quarter, compared to analyst estimates of $70.90 million. PetMed Express had a net margin of 8.86% and a trailing twelve-month return on equity of 18.44%. During the same quarter in the previous year, the firm earned $0.42 earnings per share.
View PetMed Express' earnings history.

How often does PetMed Express pay dividends? What is the dividend yield for PetMed Express?

PetMed Express announced a quarterly dividend on Monday, October 25th. Investors of record on Monday, November 8th will be given a dividend of $0.30 per share on Friday, November 19th. This represents a $1.20 annualized dividend and a dividend yield of 4.44%. The ex-dividend date of this dividend is Friday, November 5th.
View PetMed Express' dividend history.

Is PetMed Express a good dividend stock?

PetMed Express pays an annual dividend of $1.20 per share and currently has a dividend yield of 4.39%. PETS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. PetMed Express has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of PetMed Express is 96.00%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on EPS estimates, PetMed Express will have a dividend payout ratio of 94.49% in the coming year. This indicates that PetMed Express may not be able to sustain their current dividend.
View PetMed Express' dividend history.

What price target have analysts set for PETS?

3 analysts have issued 1 year price targets for PetMed Express' stock. Their forecasts range from $25.00 to $39.00. On average, they anticipate PetMed Express' stock price to reach $30.67 in the next year. This suggests a possible upside of 13.5% from the stock's current price.
View analysts' price targets for PetMed Express or view top-rated stocks among Wall Street analysts.

Who are PetMed Express' key executives?

PetMed Express' management team includes the following people:

• Matthew N. Hulett, President, Chief Executive Officer & Director
• Bruce S. Rosenbloom, Chief Financial Officer & Treasurer (LinkedIn Profile)
• Alison Berges, Secretary & General Counsel

What is Mendo Akdag's approval rating as PetMed Express' CEO?

5 employees have rated PetMed Express CEO Mendo Akdag on Glassdoor.com. Mendo Akdag has an approval rating of 46% among PetMed Express' employees. This puts Mendo Akdag in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of PetMed Express' key competitors?

Some companies that are related to PetMed Express include Amazon.com (AMZN), Netflix (NFLX), Booking (BKNG), Expedia Group (EXPE), TripAdvisor (TRIP), Overstock.com (OSTK), 1-800-FLOWERS.COM (FLWS), CarParts.com (PRTS) and Groupon (GRPN).
View all of PETS's competitors.

What other stocks do shareholders of PetMed Express own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PetMed Express investors own include Intel (INTC), NVIDIA (NVDA), AT&T (T), Cisco Systems (CSCO), Alibaba Group (BABA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Verizon Communications (VZ), Netflix (NFLX) and Micron Technology (MU).

What is PetMed Express' stock symbol?

PetMed Express trades on the NASDAQ under the ticker symbol "PETS."

Who are PetMed Express' major shareholders?

PetMed Express' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.16%), Renaissance Technologies LLC (4.03%), Penserra Capital Management LLC (2.99%), Dimensional Fund Advisors LP (2.80%), Allianz Asset Management GmbH (1.87%) and Bank of New York Mellon Corp (1.83%). Company insiders that own PetMed Express stock include Bruce S Rosenbloom, Gian Fulgoni, Menderes Akdag and Ronald J Korn.
View institutional ownership trends for PetMed Express.

Which institutional investors are selling PetMed Express stock?

PETS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Penserra Capital Management LLC, Jane Street Group LLC, Profit Investment Management LLC, Renaissance Technologies LLC, BlackRock Inc., PEAK6 Investments LLC, and Voloridge Investment Management LLC. Company insiders that have sold PetMed Express company stock in the last year include Bruce S Rosenbloom, Gian Fulgoni, Menderes Akdag, and Ronald J Korn.
View insider buying and selling activity for PetMed Express or view top insider-selling stocks.

Which institutional investors are buying PetMed Express stock?

PETS stock was purchased by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Hotchkis & Wiley Capital Management LLC, Point72 Asset Management L.P., Nierenberg Investment Management Company Inc., Richard P Slaughter Associates Inc, Aviva PLC, Man Group plc, and Pacer Advisors Inc..
View insider buying and selling activity for PetMed Express or or view top insider-buying stocks.

How do I buy shares of PetMed Express?

Shares of PETS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PetMed Express' stock price today?

One share of PETS stock can currently be purchased for approximately $27.02.

How much money does PetMed Express make?

PetMed Express has a market capitalization of $549.83 million and generates $309.21 million in revenue each year. The company earns $30.60 million in net income (profit) each year or $1.25 on an earnings per share basis.

How many employees does PetMed Express have?

PetMed Express employs 219 workers across the globe.

When was PetMed Express founded?

PetMed Express was founded in 1996.

What is PetMed Express' official website?

The official website for PetMed Express is www.1800petmeds.com.

Where are PetMed Express' headquarters?

PetMed Express is headquartered at 420 SOUTH CONGRESS AVENUE, DELRAY BEACH FL, 33445.

How can I contact PetMed Express?

PetMed Express' mailing address is 420 SOUTH CONGRESS AVENUE, DELRAY BEACH FL, 33445. The company can be reached via phone at (561) 526-4444 or via fax at 561-526-4445.